theophylline has been researched along with lansoprazole in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aubé, J; Chu, YK; Chung, D; Golden, JE; Guo, H; Jonsson, CB; McKellip, S; Noah, JW; Rasmussen, L; Roy, S; Schroeder, CE; Smith, LH; Smith, RA; Sosa, M; Sotsky, J; Tower, NA; White, EL; Yao, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Cavanaugh, JH; Granneman, GR; Karol, MD; Locke, CS | 1 |
| Ihara, N; Kokufu, T; Koyama, H; Mori, S; Nakajima, K; Ohta, T; Sugioka, N | 1 |
| Flockhart, DA; Jang, IJ; Ko, JW; Nam, SK; Shin, JG; Shin, SG | 1 |
| Dilger, K; Klotz, U; Zheng, Z | 1 |
| Fask, A; Saltiel, E | 1 |
| Goldwater, DR; Hunt, RH; Pan, WJ; Pilmer, BL; Zhang, Y | 1 |
| Onur, R; Yenisehirli, A | 1 |
| Gunawardhana, L; Lee, RD; Mulford, D; Vakily, M; Wu, J | 1 |
| Arand, M | 1 |
| Al-Huniti, N; Bui, KH; Cheung, SYA; Johnson, TN; Li, J; Xu, H; Zhou, D; Zhou, W | 1 |
1 review(s) available for theophylline and lansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for theophylline and lansoprazole
| Article | Year |
|---|---|
Pharmacokinetic interaction between lansoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Theophylline | 1995 |
Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Bronchodilator Agents; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Prospective Studies; Proton Pumps; Reference Values; Single-Blind Method; Theophylline; Time Factors; Volunteers; White People | 1999 |
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Bronchodilator Agents; Cross-Over Studies; Cytochrome P-450 CYP1A2; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Theophylline | 1999 |
Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Biological Availability; Bronchodilator Agents; Delayed-Action Preparations; Drug Interactions; Humans; Lansoprazole; Linear Models; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides; Theophylline | 2000 |
Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anticoagulants; Anticonvulsants; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Diazepam; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Phenytoin; Proton Pump Inhibitors; Theophylline; Warfarin; Young Adult | 2009 |
21 other study(ies) available for theophylline and lansoprazole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.
Topics: Animals; Antiviral Agents; Benzamides; Drug Evaluation, Preclinical; Encephalitis Virus, Venezuelan Equine; Encephalomyelitis, Venezuelan Equine; Heterocyclic Compounds, 2-Ring; Mice, Inbred C3H; Mice, Inbred C57BL; Piperazines; Quinazolinones; Small Molecule Libraries; Structure-Activity Relationship; Virus Replication | 2014 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effects of lansoprazole on pharmacokinetics and metabolism of theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Bronchodilator Agents; Drug Interactions; Enzyme Inhibitors; Humans; Individuality; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Theophylline | 1995 |
Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diazepam; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pharmacies; Prevalence; Proton Pump Inhibitors; Retrospective Studies; Theophylline; Warfarin | 1999 |
Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Heart Atria; Imidazoles; In Vitro Techniques; Lansoprazole; Male; Milrinone; Myocardial Contraction; Omeprazole; Ouabain; Phosphodiesterase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Theophylline; Verapamil | 2005 |
[Nocturnal shortness of breath: in asthma look for reflux -- is it worthwhile?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Bronchodilator Agents; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Theophylline; Time Factors; Treatment Outcome | 2008 |
Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Topics: Acetates; Analgesics, Opioid; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Bronchodilator Agents; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Esomeprazole; Histamine H1 Antagonists, Non-Sedating; Humans; Infant; Infant, Newborn; Itraconazole; Lansoprazole; Loratadine; Models, Biological; Ondansetron; Pharmaceutical Preparations; Pharmacokinetics; Proton Pump Inhibitors; Quinolines; Serotonin Antagonists; Sufentanil; Sulfides; Theophylline; Tramadol | 2018 |